Positively Positive – Living with HIV/AIDS:
HIV/AIDS News
HIV, AIDS and Infectious Disease News
from around the world
Worldwide 92.2 million people have been infected with HIV.
Worldwide 44.2 million people with HIV have died.
Worldwide, 41 million people were living with HIV at the end of 2025.
.
Practicing Safe Sex is our best resource in preventing HIV infection through sexual contact.
Sexual contact accounts for 95 percent of all new HIV infections worldwide.
Safe Sex = Disease Prevention – STAY SAFE!
Use A Condom Every Time!
“HIV needs to be in the media each and every day as most people only see snippets of news and these are not effective enough. For this reason, in 2007, I decided to include an HIV/AIDS News page where people could find information on many HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immune Deficiency Syndrome) related issues, Infectious Disease,
and more.
I collaborate with individuals, groups, and organizations throughout the world, to include their HIV/AIDS news articles, press releases, events, workshops, conferences, and more on PositivelyPositive.ca. News items stay on the HIV/AIDS News page for a month,
and then News items go into the HIV/AIDS News Archives.”
Bradford McIntyre
Hepatitis B reactivation after switch to injectable treatment: rare, but proceed with caution
19 November 2026 - By Keith Alcorn - aidsmap - Although hepatitis B reactivation is rare after a switch to injectable cabotegravir / rilpivirine, people with HIV require careful monitoring before and after a switch to assess protection against hepatitis B and reactivation risks, studies presented at last week’s International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026) suggest.
Cohort studies carried out in Spain and Italy found that rates of hepatitis B reactivation after switching to injectable cabotegravir / rilpivirine were low or non-existent. But the Italian study highlighted the risk of poor or non-existent immunity to hepatitis B despite vaccination. Three vaccinated people acquired hepatitis B during the study, although their infections were asymptomatic and detected only through tests for hepatitis B core antibody (anti-HBc) and surface antibody (anti-HBs).
Read more...

Stockholm welcomes scientific experts for Europe’s leading annual public health conference
Stockholm, 18 November 2026 - European Centre for Disease Prevention (ECDC) - As new infectious disease threats emerge in an increasingly interconnected world, policymakers, public health professionals and researchers from across Europe and beyond are gathering in Stockholm this week for the 20th edition of the European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE).
Organised by the European Centre for Disease Prevention and Control (ECDC), the annual conference takes place from 18 to 20 November in a hybrid format, welcoming more than 3 000 participants both in person and online. It provides an opportunity to share the latest scientific findings, exchange practical experience and explore how research can better inform the prevention and control of infectious diseases.

Urgent action needed to safeguard the effectiveness of antibiotics
Stockholm, 18 November 2026 - European Centre for Disease Prevention (ECDC) - With mounting evidence that antibiotic-resistant bacteria are continuing to spread and treatment options are becoming increasingly limited, urgent action is needed to safeguard the effectiveness of antibiotics, the European Centre for Disease Prevention and Control (ECDC) said on the occasion of European Antibiotic Awareness Day.
“We are still behind with several of the EU’s 2030 targets to counter antimicrobial resistance. However, the good news is that we can now look beyond just numbers,” said ECDC Director Pamela Rendi-Wagner. “Innovations such as faster genomic surveillance mean that we can now assess better and more rapidly how resistant bacteria spread and how they evade antibiotics. This in turn means we can act sooner to stop transmission, more effectively guide treatment decisions, and identify where new antibiotics are most urgently needed.”
Weill Cornell Receives $3 Million to Study HIV as Trump Restructures HIV Grants
November 17, 2026 - By Matteus Jasik and Lila Davis - The Cornell Daily Sun - “I’m honored that NIMH has given us the unique opportunity to move cutting-edge research forward that we hope will ultimately transform the lives and care of people with HIV,” Prof. Lishomwa Ndhlovu, immunology in medicine, a researcher at Weill Cornell and co-director of the center told the Cornell Chronicle.
Ndhlovu added that he hopes the center will close a “critical gap” in current treatment.

Young Americans have no memory of AIDS at its worst – they’re still at risk of infection, even when HIV doesn’t feel like a threat
November 17, 2026 - By Andrés Henao, University of Colorado Anschutz - The Conversation - For Americans who came of age in the 1980s and early 1990s, HIV/AIDS was difficult t o ignore. Hospitals were filled with young people sick with infections and cancers rarely seen in healthy adults. Friends and partners were quickly dying. Public health officials warned that the disease, primarily transmitted through sexual contact or sharing drug needles, had no effective treatment.
At the height of the U.S. epidemic in 1995, more than 56,000 people with AIDS died in a single year. Then antiretroviral therapy – medications that stop HIV from multiplying – transformed the epidemic. Over the next three years, AIDS diagnoses fell by 45%, while deaths among people with AIDS fell 63%.
Someone who is 20 years old today was born into a very different world. HIV is now a manageable chronic infection for people who can access and remain on treatment. As of 2025, over 20% of people around the world with HIV were unable to access treatment. As an infectious diseases physician caring for people with HIV, I have watched that transformation change not only the lives of my patients, but also the way people think about this once fatal disease.
That success raises an unusual public health question: How do you prevent new infections in a generation that grew up with no memory of a disease at its worst?

HIV, Stigma and Society: Twelve Years Later
November 17, 2026 - Bristish Columbia Centre for Excellence in HIV/AIDS (BC-CfE) - BC-Cfe IN-PERSON EVENT LEARNING SERIES)
November 25, 2026 from 12:00 – 1:00 PM (PST).
This Learning Series will be presented by:
Dylan Wall | Health Initiative for Men (HIM),
Dr. Mark Gilbert | University of British Columbia (UBC),
Dr. Mark Hull | BC Centre for Excellence in HIV/AIDS (BC-CfE)
Register online
Hybrid (in-person and remote via GoToWebinar)
‘Orwellian’: HIV scientist’s ordeal lays bare Trump officials’ interference in grant-making
Nove 16, 2026 - By Jessica Glenza - The Guardian - Researchers forced to scrap original studies as NIH rethinks grants not in ‘alignment’ with administration’s priorities
Dr Jade Pagkas-Bather received her first grant from the National Institutes of Health (NIH) in June 2025 – a milestone in any researcher’s career.
She planned to study basic income as a medical intervention: her randomized control trial would test whether monthly grants of $500-cash helped poor, HIV-positive young people in Chicago stick with treatment. Her hypothesis was as straightforward as it was cutting.
Read more...

NIH Faces Threats to Science Funding
November 16, 2026 - By Liz Highleyman - POZ - In recent months, the administration has delayed grant awards to HIV clinical trials networks.
In the early days of the second Trump administration, the Centers for Disease Control and Prevention and foreign aid were among the first targets, but now the National Institutes of Health (NIH) is under fire. As the world’s largest public funder of biomedical research, the NIH has historically supported the science that laid the groundwork for HIV prevention and treatment as well as ongoing efforts to find a cure. But funding cuts and policy changes threaten to undermine that legacy.
Read more...
Out of Sync
November 16, 2026 - Florida International University - Uncovering how HIV disrupts the lung’s internal clock, fueling inflammation
People living with HIV face a greater risk of developing lung diseases such as emphysema and chronic obstructive pulmonary disease (COPD) at a much younger age—even if they have never smoked.
While clinicians have long noted disrupted sleep patterns in people with HIV, FIU researchers have now delivered the first report detailing the molecular mechanism of HIV-associated circadian disruption specifically in the lung. In a study published in Communications Biology, the team showed that the HIV protein Tat interferes with the lungs’ internal molecular “clock”—the timekeeping system that governs daily lung function and immune responses. This disruption unleashes inflammation that damages airway tissue and sets the stage for disease.

In ‘Elsinore,’ People Lie About AIDS and Everything Else
November 16, 2026 - By Mark S. King - My Fabulous Disease - In a wrenching scene in the new film Elsinore, Ian Charleson (played by Andrew Scott) is forced to make two painful admissions from his hospital bed to his working class parents. The year is 1989, and Ian must admit that he is a gay man and that he has AIDS. That conversation was a common one-two punch between gay men and our families during the darkest years of the plague.
In the film, the parents’ shock is eclipsed only by the anguish of their son, who apologizes for years of deceit and for withholding his life from them. That Ian feels the need to apologize for hiding his queerness and his HIV diagnosis – two things this world does not treat kindly – may be the saddest part of all.
U.S. Has Lost Its Measles Elimination Status: ‘Sad Thing for the U.S. and for the World’
November 16, 2026 - By Cara Lynn Shultz - People - The loss of the designation after 26 years comes amid surging cases of the infectious disease and multiple fatal outbreaks
The United States has officially been stripped of its measles elimination status, which it has held since 2000.
The Pan American Health Organization (PAHO) convened to remove the designation amid an ongoing, progressive rise in measles cases in the U.S., caused by declining rates of vaccinations. This year, there have been more than 5,400 measles cases reported, more than double the cases reported in 2025. In both years, the outbreaks turned deadly. For comparison, in 2024, there were just 285 cases.
Read more...
U.S. loses measles elimination status as cases hit record level
November 14, 2026 - By Jessica Nix and Rachel Cohrs Zhang - NATIONAL POST - This represents a national failure to control the highly contagious disease and is likely to prompt warnings about travel to the U.S.
The U.S. lost its long-standing measles eradication status after the disease continued to spread through the past year and broke case records, according to people familiar with the decision.
Read more...
Researchers find new way to protect the brain from HIV and opioid damage
November 13, 2026 - By Shelby Purdy - News from Texas A&M Health - HIV and opioids disrupt the brain’s natural DNA repair system, but an existing multiple sclerosis drug might help reverse the damage
People living with HIV continue to struggle with memory loss, difficulty concentrating and poor decision-making, even as antiretroviral treatments have dramatically improved life expectancy. For patients who also use opioids—which may be prescribed to manage the chronic pain that can accompany HIV—these cognitive problems can be even worse. Until now, scientists haven’t understood exactly why.
Texas A&M Health researchers say they’ve uncovered a key factor in HIV- and opioid-use-related cognitive impairment—and it could point to a promising new way to protect the brain. In a new study published in Cell Death & Disease, a Nature Portfolio journal, the research team revealed that HIV and opioids combine to disrupt the brain’s natural DNA repair system. This damage leads to ongoing inflammation and cognitive impairment. But the researchers believe an existing drug, approved by the Food and Drug Administration (FDA), might help reverse the effects.

SADC health ministers warn disruptive UNAIDS reform could jeopardize 2030 AIDS goal
GENEVA/DURBAN, 13 November 2026 - UNAIDS - Ministers of Health and Ministers responsible for HIV and AIDS from across the Southern African Development Community (SADC) have reaffirmed their strong support for the continued work of the United Nations Joint Programme (UNAIDS) during a meeting in Ethekwini, Durban in the Province of Kwazulu-Natal, South Africa, between 9-12 November. The health authorities are calling for reform that protects the institution's essential functions, including continued generation of strategic information and analysis that increases the understanding of the AIDS epidemic, expertise and ability to continue to support countries.
How Will the Midterms Affect People With HIV in the U.S.? Three Experts Dish the Details
Nove 13, 2026, - By Tim Murphy - TheBody - We’re nearing two years of the Trump 2.0 administration and a GOP-led Congress highly obedient to the president. Although some of the most devastating proposed cuts to programs specifically serving people with HIV did not occur, we have seen devastation for broader health coverage programs that interlock closely with HIV.
Read more...

Watch: 30-Year Reunion of “Rent” on Broadway Raises $4.6M for HIV
November 13, 2026 - By Trent Straube - POZ - The “Rent” anniversary performance raised funds for Broadway Cares/Equity Fights AIDS, with support from ViiV and the Gates Foundation.
In 1996, the groundbreaking HIV-themed rock musical Rent debuted on Broadway. A few weeks ago, on October 26, three decades of Rent performers—many who became stars of the stage and screen—reunited for an anniversary performance that was livestreamed to over 65,000 viewers across the globe.
Fittingly, the one-night-only Rent performance was a fundraiser for Broadway Cares/Equity Fights AIDS. The event brought in $4,571,464 to provide lifesaving meds and HIV services along with 1.8 million nutritious meals to people facing food scarcity.
Read more...
CDC eliminates $29 million for HIV prevention in Texas
November 12, 2026 - By Sasha Draeger-Mazer - THE TEXAS TRIBUNE - The program, which helped organizations pay for HIV testing and outreach services, is the latest casualty in a series of public health funding cuts by the federal government.
The federal government has cut $29.2 million from Texas health organizations that test thousands of people for HIV directly in their communities, the latest in a series of public health funding cuts statewide.
Read more...

Long-acting lenacapavir combined with other long-acting drugs for HIV treatment
November 12, 2026 - CATIE News - Canadian AIDS Treatment Information Exchange (CATIE) - Researchers studied a novel combination of long-acting (LA) HIV treatments
A combination of LA lenacapavir + LA cabotegravir was used by 46 people with HIV
Taken over two years, these drugs were highly effective at suppressing HIV
The first long-acting (LA) HIV treatment regimen is a combination of two drugs:
cabotegravir – an integrase inhibitor
rilpivirine – a non-nucleoside reverse transcriptase inhibitor (NNRTI), also known as a non-nuke
This combination, sold as Cabenuva in Canada and some other high-income countries, was initially approved for once-monthly dosing administered by a healthcare provider as intramuscular injections deep into the buttocks. Subsequent clinical trials used higher doses of both drugs and found that the combination could suppress HIV when administered via deep intramuscular injections into the buttocks every two months.

Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards®
FOSTER CITY, Calif.--(BUSINESS WIRE)-- November 12, 2026 - Gilead - Ahorita Mismo! campaign encourages Latino communities to start conversations about HIV testing and prevention right now
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new collaboration with TelevisaUnivision and the 27th Latin GRAMMY Awards that will bring HIV prevention awareness into one of the most prominent cultural moments for Latino audiences.
The collaboration comes at a crucial time for Latino communities in the United States. In 2024, Hispanic/Latino people were 67% more likely than the U.S. population overall to be diagnosed with HIV, with a diagnosis rate of 18.9 per 100,000 compared with 11.3 per 100,000 overall.

United Nations Association of New York to Honor amfAR with Humanitarian Award
NEW YORK, November 12, 2026 - amfAR, The Foundation for AIDS Research - The award will be presented during a World AIDS Day Commemoration at UN Headquarters
In recognition of its more than 40 years of leadership in the global fight against HIV/AIDS, the United Nations Association of New York (UNA-NYC) will present amfAR with its Humanitarian Award on World AIDS Day, December 1, 2026. amfAR CEO Kyle Clifford will accept the award alongside fellow honorees Annie Lennox; Cleve Jones, architect of the AIDS Memorial Quilt; Levi Strauss & Co.; and Dr. David Ho, whose research led to the development of antiretroviral therapy 30 years ago.

Jacques Initiative Brings HIV Prevention Education Into Baltimore Beauty Shops Through Community-Designed Program
November 11, 2026 - By Jennifer Gonzales - University of Maryland School of Medicine - New study in the Journal of the International AIDS Society highlights how trusted community relationships can help address barriers to HIV prevention among Black women.
What if a conversation about HIV prevention began not in a doctor's office, but in a neighborhood beauty shop?
A new study from the JACQUES Initiative at the University of Maryland School of Medicine highlights the potential of Tea Talk, a community-designed sexual health education initiative that brings HIV prevention information into Black-owned beauty shops across Baltimore. Published October 26 in the Journal of the International AIDS Society (JIAS), the study demonstrates how partnering with trusted community professionals can help make sexual health education more accessible, culturally responsive and relevant to the women it aims to reach.

CANADIARY: Janet Conners
NOVEMBER 11, 2026 - CANADIARY - In 1989, a lab technician in Halifax was told by doctors that she could not possibly have HIV.
She insisted on the test anyway.
She was positive, and she decided she was not going to die quietly.
She was born Janet Pritchard in Vancouver in 1956, the middle of six children.
Years later she would joke about it. In a family that size, she said, you had to lobby for your survival.
By 1981 she was a single mother with a young son, working as a lab technician at the infectious disease clinic of the Victoria General Hospital in Halifax.

Heart Disease Is Leading Cause of Death for People With HIV
November 11, 2026 - By Liz Highleyman - POZ - Lifestyle changes and statin therapy can reduce cardiovascular risk for people aging with HIV.
Deaths attributable to cardiovascular disease have increased over the past 25 years and now exceed AIDS-related deaths—especially among HIV-positive people ages 45 and older—though opportunistic illnesses are still a concern, according to a study presented at IDWeek 2026. These findings underscore the need for HIV care that focuses on overall health, including heart disease prevention, along with antiretroviral treatment.
Read more...
Patients with HIV ‘isolated in single rooms’ and told to use commodes instead of toilets, Oireachtas health committee told
11 Nov 2026 - By Eilish O'Regan - Irish Independent - A nurse who has HIV and appeared in a public awareness campaign has warned of the widespread stigma and discrimination experienced by people living with the virus.
Aoife Commins from Co Galway said misinformation within healthcare settings is causing harm, delaying diagnoses and preventing people from accessing vital treatment.
Read more...

As SNAP benefits run low, people with HIV can struggle to stay on treatment
Nov 10, 2026 - By Desiree Guerrero - ADVOCATE - Researchers found that people kept up with their HIV medication better after receiving SNAP benefits.
Despite major advances in HIV treatment, food and housing insecurity can still make it difficult for people living with the virus to take their medication consistently, according to an article by WHYY News.
Dr. Aaron Richterman, an infectious diseases specialist at Penn Medicine in Philadelphia, told WHYY that he would often hear patients say, “How am I supposed to take my medicine when I don’t have enough to eat?”
Read more...
HIV activism offers a roadmap for tackling weight stigma
November 10, 2026 - Wits University - University of the Witwatersrand (Wits University), Johannesburg - Although HIV and obesity are not mirror images, lessons from the HIV response could accelerate fairer and more effective care for people living with obesity.
These were the findings in the paper titled Weight gain in people living with HIV published as part of The Lancet HIV Series on 8 November.
This Series highlights how HIV and weight stigma can intersect, and how community-led, integrated services can help address both.
By adapting HIV’s activist-built tools, i.e., community leadership, stigma measurement, legal protection and integrated treatment access, weight-stigma reduction can move beyond blame and toward care that treats obesity as a health issue, not a moral failing.

TaiMed Biologics Announces Publication in The Lancet HIV of Phase 1b/2a Study of Long-Acting Dual-Antibody HIV Maintenance Regimen TMB-365/TMB-380
November 10, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics - - Further analysis of previously announced Phase 2a results showed 94% of evaluable participants maintained viral suppression through 24 weeks, with no confirmed virologic failures -
- Study evaluated TMB-365/TMB-380 without pretreatment susceptibility screening and identified pharmacokinetic findings that informed the ongoing Phase 2b study -
- Publication and presentation at HIV Glasgow 2026 provide peer-reviewed support for TaiMed’s differentiated host- and virus-targeted, all-antibody approach to long-acting HIV treatment -
TaiMed Biologics Inc. (TPEX: 4147), a commercial-stage CD4-targeted biologics company advancing antibody-based therapies for long-acting HIV treatment, today announced the publication in The Lancet HIV of results from a Phase 1b/2a clinical study evaluating TMB-365 in combination with TMB-380 as a long-acting maintenance regimen in people living with HIV who were virologically suppressed on oral antiretroviral therapy (ART). These same findings were also delivered in an oral presentation at this year’s HIV Glasgow meeting held in Glasgow, Scotland, and the scientific article publication is available electronically on The Lancet HIV’s website.
Community-based orgs pivot services as federal HIV prevention funding shifts to states
November 10, 2026 - By Skye Crawford - North Carolina Health News - This summer, the CDC announced it would no longer fund community groups that work to prevent HIV, leading one group in Charlotte to close entirely.
Just three days before shutting down, PowerHouse 2.0 in Charlotte tested and identified someone newly positive with HIV.
The organization had been around for 16 years, offering free HIV screenings and sexually transmitted infection prevention services for Black men in the community who have sex with men. (HIV is the virus that causes AIDS.) It shut down at the end of September after the CDC redirected HIV prevention funds to state and local health departments.
“To just be able to end the funding stream, it does not mean that the work needs to be ended,” said Ra’Shawn Flournoy, CEO at Quality Comprehensive Health Care, the parent organization of the PowerHouse program.
In July, the Trump administration directed the CDC to not renew its five-year grant that has invested almost $240 million in HIV prevention directly through 96 community-based organizations across the country since 2021.
“Normal is the perfect word”: participants describe switching to weekly HIV treatment
10 November 2026 - By Zekerie Redzheb - aidsmap - Taking HIV treatment once a week may make it easier to fit into everyday life and reduce the daily reminder of living with the virus. In the ISLEND-2 study, most people who switched from daily treatment to an investigational weekly tablet containing islatravir and lenacapavir favoured their new regimen and the reasons for this went beyond convenience.
Read more...

Alimatravir, a once-monthly oral HIV prevention pill, moves forward in clinical trials
November 10, 2026 - Canadian AIDS Treatment Information Exchange (CATIE) - A second phase trial of HIV prevention pill alimatravir included people at low risk
Results with 350 people so far suggest that it is generally safe and well tolerated
A once-monthly pill could offer more options for long-acting PrEP without injections
In a short study involving people with HIV, scientists confirmed that alimatravir’s anti-HIV activity, previously observed in the laboratory, was also seen in people. This finding is important because it confirms that the drug has anti-HIV activity in the body—a crucial step before alimatravir is evaluated in future trials for HIV prevention.
Alimatravir is being tested as a prevention pill taken once monthly for people without HIV..
Another benefit of viral suppression is that people with HIV who have an undetectable viral load cannot pass on the virus to their sexual partners.
In a phase 1 clinical trial to assess preliminary safety, alimatravir was found to be generally safe in people without HIV.
Russia: HIV spreads beyond risk groups in 27 regions, epidemiologists say
November 9, 2026 - By Марфа Васильева - Euronews - In 27 regions of the Russian Federation, the immunodeficiency virus is spreading among the entire population, not only risk groups, according to the latest Rospotrebnadzor data. People increasingly pass the virus to one another, often unaware they are infected.
Read more...
Moving to HIV self-care would be better and cheaper for Africa
9 November 2026 - By Elna Schütz - aidsmap - A recent study in The Lancet Global Health found that offering more self-administered HIV services would improve results and save costs of care. It modelled the effects of self-care policies in comparison to current strategies across Africa.
The research by the Institute for Global Health, University College London, and others came about in response to the recent funding crisis of HIV services that has particularly affected African countries.
Read more...
Cambodian AIDS Authority rejects ‘viral’ claims of HIV outbreak
PHNOM PENH - Novemnber 9, 2026 - By Niem Chheng - Asia News Network - In a November 8 statement, the authority noted that data from the HIV/AIDS surveillance and response monitoring system managed by the Ministry of Health showed no evidence of an outbreak.
The National AIDS Authority has categorically rejected social media claims that Cambodia is experiencing an uptick of HIV infections. It highlighted that the number of new infections in the Kingdom continues to decline and offered statistics to support this.
Read more...
Uganda AIDS Commission defends HIV-positive youth pageant amid stigma debate
Novemnber 8, 2026 - By Elvis Basudde Kyeyune - monitor.co.ug - Dr. Byamukama emphasised that the initiative focuses on empowerment rather than rewarding the infection
Read more...
INRS and the Pasteur Network bring together scientists from 25 countries in Québec to strengthen the fight against pandemics
LAVAL (QUEBEC), November 6, 2026 – Institut national de la recherche scientifique - INRS - Held in North America for the first time, the Pasteur Network Annual Meeting highlighted how artificial intelligence and emerging technologies can advance global health preparedness and response
The Institut national de la recherche scientifique (INRS) and the Pasteur Network brought together specialists in infectious diseases, public health, and biomedical research from 25 countries in Laval, Québec, from November 3 to 5, 2026, for the Pasteur Network Annual Meeting (PNAM).
Held in North America for the first time, the international gathering provided a unique forum for scientific leaders, researchers, and public health experts to explore how artificial intelligence and emerging technologies can strengthen pandemic preparedness and response. Over three days, participants exchanged knowledge, shared best practices, and reinforced collaborations to address current and future global health challenges.
Long-Acting ART in the Real World: New Data on Efficacy, Persistence, and Nonsuppression Timing
Nov 6, 2026, 2026 - Benjamin Young, M.D., Ph.D.Myles Helfand, Executive Editor - TheBodyPro - A new tranche of real-world data from a major Spanish study gives us further evidence that long-acting antiretroviral therapy with cabotegravir/rilpivirine (CAB/RPV) has real staying power once people switch to it. It also helps us begin to understand some of the specific reasons why CAB/RPV is sometimes unsuccessful—and gives us a sense of when that is most likely to become apparent.
Read more...

New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)-- November 6, 2026 - Gilead - - Zero HIV Acquisitions Occurred Among Participants Receiving Twice-Yearly Lenacapavir During the 52-Week Study Period -
- PURPOSE 5 Study Findings Highlight the Potential of Long-Acting HIV Prevention Option to Address Persistence Challenges with Up to a Full Year of Protection After Second Dose -
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from the PURPOSE 5 trial showing significantly higher persistence—defined as consistent and continuous on-time use—among people starting twice-yearly injectable lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP), compared with those starting daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF). The trial included people in the United Kingdom (UK) and France who would benefit from PrEP. These data will be presented at HIV Glasgow 2026.
Despite substantial progress in HIV prevention, approximately 1.2 million people acquired HIV globally in 2025, according to UNAIDS, underscoring the need for prevention options that better support long-term use and protection. Persistence on PrEP remains one of the most important determinants of real-world prevention effectiveness. Daily oral F/TDF is currently the most commonly used oral PrEP medication globally.

HIV can change to evade an antibody, but escaping may come at a cost
November 6, 2026 - By Yulisha Naidoo - University of Cape Town - UCT - A South African-United States study has uncovered how HIV can evolve to resist an antibody designed to prevent infection, offering clues for developing stronger antibody-based prevention strategies.
Imagine a key designed to fit a lock. Change the shape of the lock, and the key may no longer work. HIV can do something similar. The virus can change the part of its surface that an antibody recognises, making it harder for the antibody to block infection. But these changes may also come at a cost to the virus itself.
In a study published in Nature Microbiology, researchers investigated how HIV evolved after people acquired the virus despite receiving VRC01, a broadly neutralising antibody designed to block HIV from entering human cells.

The Legacy Chest is now live!
November 6, 2026 - Realize - More than 30 stories. Over 220 minutes of lived experience. A legacy that must not be lost.
The Legacy Chest is an online archive of stories, reflections and testimonies from long-term and lifetime survivors of HIV. It brings to the forefront the voices of people who have lived through the HIV/AIDS pandemic, documenting decades of experience, activism, resilience and community building.
The Legacy Chest est maintenant en ligne!
6 novembre 2026 Réalise - Plus de 30 histoires. Plus de 220 minutes de témoignages sur des expériences vécues. Un héritage qui ne doit pas tomber dans l’oubli.
The Legacy Chest est une archive en ligne d’histoires, de réflexions et de témoignages de survivants du VIH à long terme et depuis leur naissance. Cette initiative met de l’avant les voix des personnes qui ont vécu la pandémie du VIH/sida, en documentant des décennies d’expérience, de militantisme, de résilience et de création de communautés.

Joint Statement from Ribbon – A Center of Excellence and The Reunion Project
November 5, 2026 - Ribbon - THE REUNION PROJECT - North American Partners Celebrate the Launch of the HIV Long-Term Survivors Legacy Chest
A Center of Excellence and The Reunion Project join our colleagues at the European AIDS Treatment Group (EATG) and Realize in Canada in celebrating the November 4 launch of the Legacy Chest, an international collection of personal stories from long-term and lifetime survivors of HIV.
The Legacy Chest is part of the Long-Term Survivors of HIV – Honouring the Past, Shaping the Future project, led by EATG in partnership with our three organizations. The collection includes more than 30 recorded stories, totaling over 220 minutes, from people whose experiences span decades of the HIV epidemic.
Tennessee judge extends block on immigration checks in HIV/AIDS program
NOVEMBER 5, 2026 - By Anita Wadhwani - Tennessee Lookout - The state Health Department intends to verify immigration status of patients in the healthcare program even if nonprofit agencies that provide direct care refuse, a state lawyer said.
A Nashville judge on Wednesday continued to block the Tennessee Department of Health from demanding proof of citizenship or immigration status from HIV-positive individuals who are enrolled in a safety-net healthcare program.
Chancellor I’Ashea Myles’ extension of a temporary restraining order, first issued Oct. 21, prevents the state from imposing immigration status checks in the Ryan White HIV/AIDS program until at least next week, as she weighs arguments for a longer injunction.
The order also applies to a companion program called Housing Opportunities for People with AIDS. The programs, which provide federal funding to every state, have served as the cornerstone of the U.S. government’s response to HIV/AIDS for more than 30 years.
AIDS Activist James Rann of Waves Salon Dies at 83
Nov 4, 2026 2026 - By Mary-Jo Avellar - The Provincetown Independent - AIDS activist, hair stylist, and artist James Edward Rann died on Oct. 1, 2026 at Seashore Point in Provincetown. Peter McDonough, his husband of 31 years, said the causes of death were AIDS and complications of a fall. James was 82.
Read more...
Without US funding, Zimbabwe could see over 75,000 new HIV infections in a year
4 November 2026 - By Krishen Samuel - aidsmap - The US has recently ended all health funding to Zimbabwe after the two countries failed to reach consensus regarding the terms of a bilateral agreement.
The consequences for HIV prevention will likely be dire, according to a new modelling study: 75,440 new infections within a year, over half from disruptions to antiretroviral treatment (ART) programmes, and a quarter from lack of access to prevention programmes, such as PrEP and voluntary medical male circumcision.
Read more...
Recent Medicaid ruling is a reprieve for HIV/AIDS community
November 3, 2026 - By Sarah Boden - CIDRAP - Center for Infectious Disease Research & Policy - University of Minnesota - Americans with HIV and other complex medical needs got mostly good news about their Medicaid coverage last week.
A ruling out of the US District Court in Boston found that the Centers for Medicare and Medicaid Services (CMS), led by Mehmet Oz, MD, exceeded its regulatory authority with a provision that sought to limit which Medicaid enrollees are exempt from a new work requirement by narrowing the definition of “medically frail.”
Judge Richard G. Stearns, however, upheld two other CMS provisions affecting medically frail adults that were opposed by states that sued CMS. The plaintiffs had argued, in part, that these new administrative hurdles from CMS would inflict harm and chaos.
Because Medicaid is a publicly funded insurance program for low-income people, advocates and policy experts warn that the fallout of this ruling and possible appeal could still result in some Americans with HIV losing coverage. This could hinder their access to lifesaving antiretroviral therapy (ART), carrying serious implications for public health.

FDA Approves Generic Lenacapavir PrEP — But Not for the U.S.
November 3, 2026 - By Eva Lorenz - POZ - An inexpensive generic version of the twice-yearly injectable prevention drug will be offered in more than 100 countries with a high burden of HIV.
The generic version, from India’s Dr. Reddy’s Laboratories, will be offered in more than 100 low-income countries at an annual cost of $40. Initial supplies could be distributed by the end of this year, according to Unitaid, which supported the development and regulatory filing of the generic.
But generic lenacapavir will not be available in the United States, where Gilead’s brand-name version, Yeztugo, costs around $28,000 a year. The FDA approval enables U.S. government procurement of the generic while the branded product remains under patent and can help speed up regulatory approval in other countries. The final patents on Yeztugo do not expire until 2040.
Read more...
U.S. FDA approves first generic injectable lenacapavir for HIV prevention
Geneva, 2 November 2026 - Unitaid - The U.S. Food and Drug Administration (FDA) has approved the first generic long-acting injectable for HIV prevention, just 16 months after the approval of the originator product. A novel regulatory strategy resulted in one of the fastest timelines to approval for a major HIV innovation to date.
Developed by Dr. Reddy’s Laboratories with financial, technical, and regulatory support from Unitaid, Wits RHI, and the Clinton Health Access Initiative (CHAI) to accelerate the product’s development and regulatory filing and speed up lenacapavir’s market entry.
Under the existing partnership agreement, Dr. Reddy’s lenacapavir injection will be available at US$40 per person per year for the 120 low- and middle-income countries included in Gilead’s voluntary license.
First supplies of the generic are expected to reach countries before the end of the year, with broader availability in 2027.
Dr. Reddy’s Laboratories has secured FDA tentative approval for the first generic injectable lenacapavir, just 16 months after a Gilead’s originator product was approved for HIV prevention. The milestone brings an affordable version of the highly effective, twice-yearly HIV prevention injection closer to people in 120 low-and middle-income countries, with initial supplies expected to reach countries by end of 2026.
New service brings geriatric care to older adults living with HIV
November 2, 2026 - By Paul Govern - Vanderbilt Health - By 2040 more than one in three patients with HIV is expected to be 65 or older.
When Jessica Castilho, MD, MPH, meets a patient newly diagnosed with HIV (human immunodeficiency virus), she delivers news that would have been hard to imagine a generation ago: &ldquo:HIV does not shorten one’s life expectancy like it once did.”
That progress has created a new need, and Vanderbilt Health has launched a service to meet it. The Older Adult Care (OAC) Service at the Comprehensive Care Clinic (CCC), the HIV clinic at Vanderbilt Health One Hundred Oaks, began seeing patients in August, bringing geriatric specialty care into the clinic where patients already receive their HIV care and primary care.
Rutgers Is Awarded $3.6 Million to Improve Heart and Metabolic Health in Older Adults With HIV
November 2, 2026 - By Nicole Swenarton - RUTGERS - Researchers will examine chronic disease risks, gaps in treatment and medication effectiveness and safety among 50 and older adults with HIV
With a $3.6 million grant from the National Institutes of Health, Rutgers researchers will conduct one of largest and most comprehensive studies of heart and metabolic conditions among older adults living with HIV.
Advances in treatment have helped people with HIV live longer than ever before, but as this population ages, a new challenge is emerging: managing chronic conditions such as heart disease, diabetes and kidney disease, often with limited evidence about which treatments work best.
“We have made tremendous progress in helping people with HIV live longer, but the evidence guiding treatment of age-related conditions has not kept pace,” said Chintan Dave, a core member of the Center for Pharmacoepidemiology and Treatment Science at the Rutgers Institute for Health, Health Care Policy and Aging Research. “Our study will help determine who is at greatest risk, where treatment gaps exist and which medications offer the greatest benefits with the fewest harms.”
Cheap version of HIV-prevention shot raising hope in low-income countries
Nov 02, 2026 - The Associated Press - CTV News - Generic version of twice-a-year shot expected to cost $40 US a year per person
The U.S. Food and Drug Administration has approved a generic version of the world's only twice-a-year shot to prevent HIV — a big step toward making the drug available inexpensively and more quickly in 120 low— and middle-income countries.
Listen & read more...
For more HIV and AIDS News visit…
Positively Positive - Living with HIV/AIDS: HIV/AIDS News Archive

Back to Top
HIV/AIDS News
|